RNA-based therapeutics represent a fundamental shift in how diseases can be addressed at their source. Unlike traditional drugs that act on proteins, RNA modalities intervene upstream—at the RNA level, the critical link between DNA and protein.
This provides a key mechanistic advantage for precisely addressing the root cause of diseases, especially those with clear genetic origins like many rare disorders.
 
Key RNA modalities at a glance:
mRNA: Protein Replacement
Enables in vivo protein expression; widely applied in vaccines and oncology.
siRNA: Gene Silencing
Selectively degrades target mRNA to reduce pathogenic protein expression.
ASO: Splice Modulation / Knockdown
Alters RNA splicing or induces degradation, with strong impact in neuromuscular and neurological diseases.
sgRNA (CRISPR): Genome Editing Enablement
Directs genome editors for permanent DNA correction, particularly in hematologic genetic disorders.
                    

The pivotal question is not why RNA—but how to translate this potential into viable therapies for your specific targets.
 
Our one-stop RNA platform is designed to support that translation from early research to advanced development. 

These services might be just what you need:
siRNA/miRNA Synthesis In Vitro Transcription
sgRNA Synthesis Custom RNA Oligos
Antisense Oligonucleotides DNA Synthesis
Ready to move your RNA program forward? 
 
Synbio Technologies LinkedIn X Facebook Facebook

Thank you for connecting with us! Click "Subscribe" to receive valuable insights and news. If you prefer not to receive further emails, just hit "Unsubscribe" — your choice is always respected.
Synbio Technologies LLC
9 Deer Prk Dr., Suite J-25, Monmouth Junction, NJ 08852, USA